公开(公告)号：US10576097B2

公开(公告)日：2020-03-03

申请号：US15500895

申请日：2015-07-31

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yamashita ,  Tomohisa Watanabe ,  Tetsuro Hikichi

IPC: A61K39/00 ,  A61K31/7088 ,  A61K38/00 ,  A61K48/00 ,  C12N15/09 ,  C07K7/06 ,  C07K7/08 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50

Abstract: The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US20200341001A1

公开(公告)日：2020-10-29

申请号：US16753684

申请日：2018-10-05

Applicant: The University of Chicago ,  OncoTherapy Science, Inc.

Inventor： Yusuke Nakamura ,  Jae-Hyun Park ,  Sachiko Yoshimura ,  Tetsuro Hikichi

IPC: G01N33/68 ,  G01N33/569 ,  G01N33/50 ,  C12N15/85 ,  C12N5/0783 ,  C07K14/725 ,  A61K35/17

Abstract: Provided herein are methods to identify TCR-recognizing cancer-specific antigens, and TCR-engineered T cells having antigen-specific cytotoxic activity. Provided herein are engineered T lymphocytes produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the engineered T lymphocytes described herein. Provided herein are antibodies, or fragments thereof, produced by the methods described herein. Provided herein are methods of treating cancer in a subject comprising administering the antibodies described herein to a subject. In some embodiments, the therapeutic compositions (e.g., engineered lymphocytes, antibodies, etc.) and methods herein are provided as part of a kit or system.

公开(公告)号：US10793599B2

公开(公告)日：2020-10-06

申请号：US15762480

申请日：2016-10-06

Applicant: OncoTherapy Science, Inc.

Inventor： Sachiko Yamashita ,  Tetsuro Hikichi

IPC: C07K7/06 ,  A61K35/15 ,  A61K39/00 ,  A61K35/17 ,  C12N1/00 ,  C12N15/09 ,  C07K16/28 ,  A61K48/00 ,  C07K16/18 ,  C12N5/0783 ,  G01N33/50

Abstract: The present invention provides MPHOSPH1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US10676508B2

公开(公告)日：2020-06-09

申请号：US15751406

申请日：2016-08-10

Applicant: OncoTherapy Science, Inc.

Inventor： Sachiko Yamashita ,  Tetsuro Hikichi

IPC: C07K7/00 ,  C07K7/06 ,  A61K39/00 ,  C12N5/10 ,  C12N15/09 ,  A61K31/7088 ,  C07K7/08 ,  A61P35/00 ,  C07K16/18 ,  C12N5/0783

Abstract: The present invention provides DEPDC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US20200093849A1

公开(公告)日：2020-03-26

申请号：US16708134

申请日：2019-12-09

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yamashita ,  Tomohisa Watanabe ,  Tetsuro Hikichi

IPC: A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  C12N15/09 ,  C07K7/06 ,  C07K7/08 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50 ,  C07K16/18 ,  C12N5/10 ,  C07K14/705

Abstract: The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US20180346512A1

公开(公告)日：2018-12-06

申请号：US15762436

申请日：2016-10-06

Applicant: OncoTherapy Science, Inc.

Inventor： Sachiko YAMASHITA ,  Tetsuro Hikichi

IPC: C07K7/06 ,  C07K16/30 ,  G01N33/50 ,  A61K35/17 ,  A61K35/15

CPC classification number: A61K35/12 ,  A61K35/17 ,  A61K38/00 ,  A61K48/00 ,  C07K14/4705 ,  C07K16/32 ,  C12N5/10 ,  G01N33/505

Abstract: The present invention provides FOXM1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US11547723B2

公开(公告)日：2023-01-10

申请号：US16773487

申请日：2020-01-27

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yamashita ,  Tomohisa Watanabe ,  Tetsuro Hikichi

IPC: A61K38/00 ,  A61K35/14 ,  A61K39/00 ,  A61K48/00 ,  C07K16/18 ,  C07K7/06 ,  C07K7/08 ,  C12N5/10 ,  C12N15/09 ,  A61K35/12

Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US20220112241A1

公开(公告)日：2022-04-14

申请号：US17559991

申请日：2021-12-22

Applicant: OncoTherapy Science, Inc.

Inventor： Sachiko YAMASHITA ,  Tetsuro Hikichi

IPC: C07K7/06 ,  A61K35/12 ,  A61K35/17 ,  C12N5/10 ,  A61K35/15 ,  C07K16/32 ,  A61K38/00 ,  C07K16/30 ,  G01N33/50 ,  C07K14/47 ,  A61K39/00

Abstract: The present invention provides FOXM1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US11242365B2

公开(公告)日：2022-02-08

申请号：US15762436

申请日：2016-10-06

Applicant: OncoTherapy Science, Inc.

Inventor： Sachiko Yamashita ,  Tetsuro Hikichi

IPC: C07K7/06 ,  A61K35/17 ,  A61K38/00 ,  A61K35/12 ,  C12N5/10 ,  C07K14/47 ,  C07K16/32 ,  A61K35/15 ,  C07K16/30 ,  A61K39/00 ,  G01N33/50

Abstract: The present invention provides FOXM1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US10576102B2

公开(公告)日：2020-03-03

申请号：US15501125

申请日：2015-07-31

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yamashita ,  Tomohisa Watanabe ,  Tetsuro Hikichi

IPC: A61K38/00 ,  A61K35/14 ,  A61K39/00 ,  A61K48/00 ,  C07K16/18 ,  C07K7/06 ,  C07K7/08 ,  C12N5/10 ,  C12N15/09 ,  A61K35/12

Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.